The Orthopaedic Implant Company (OIC) announced today that the FDA cleared its dorsal spanning plate.
Reno, Nevada-based OIC will add the plate to its trauma implant portfolio to expand the potential clinical impact of its DRPx wrist fracture plating system.
According to a news release, the newly cleared product — which has now been commercially launched in the U.S. — represents the first and only high-value dorsal spanning plate on the market.
DRPx, which was launched in August 2021, supports a wide array of surgeons’ technique preferences while increasing cost-saving opportunities and improving the financial viability of ambulatory surgery centers (ASCs), hospitals and their patients, OIC said.
“If we want value-based care to work then implant companies have to play their part,” OIC President and CEO Itai Nemovicher said in the release. “The reality right now is that ASCs are only being reimbursed at 53% the rate we’re seeing with hospitals performing the exact same procedures, so this is where we can make a huge difference for ASCs. Adding the dorsal spanning plate to our DRPx system provides surgeons and facilities with the chance to substantially increase value on a high-volume procedure, streamline operations and get the exact same clinical results they’re getting with more expensive implant systems.”